Kartos Therapeutics is dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer. Self-described as focusing on the MDM2-p53 interaction for treatment options across selected solid tumors and hematological malignancies.

Kartos Therapeutics

Kartos Therapeutics, Inc. | 3,821 followers on LinkedIn. Dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer | Kartos Therapeutics is a privately held, clinical-stage biopharmaceutical company developing a potentially best-in-class MDM2 inhibitor. Launched in 2018 by proven industry veterans, we are a passionate team based in Redwood City, California, and Bellevue, Washington. We have brought together scientists and clinicians with a deep understanding of hematology and oncology and an experienced leadership team.

Roger Ulrich

SVP Clinical Pharmacology at Kartos Therapeutics

Greg Slatter

Pharma/Biotech Executive; Independent Board Director

Flavia Borellini

Kimberly Price

Kartos Therapeutics, Inc.

Feb 29th is #RareDiseaseDay and Kartos encourages you to learn more about the global movement that champions the cause of people living with rare diseases like #myelofibrosis .

KART

COM:KARTOSTHERA

Kartos Therapeutics